- Home
- BLRX vs KPRX Comparison
BLRX vs KPRX Comparison
Compare BLRX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | KPRX |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | Israel | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.7M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | KPRX |
|---|---|---|
| Price | $3.33 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | 28.8K | ★ 29.2K |
| Earning Date | 05-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $1.76 |
| 52 Week High | $5.05 | $3.29 |
Technical Indicators
Market Signals| Indicator | BLRX | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 52.82 |
| Support Level | $3.07 | $2.49 |
| Resistance Level | $3.53 | $2.91 |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 62.84 | 61.19 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.